UC Davis Alzheimer's Disease Research Center

加州大学戴维斯分校阿尔茨海默病研究中心

• 批准号: 10666428
• 负责人: Charles DeCarli
• 金额: $ 318.85万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10666428
• 关键词: Acceleration; Address; Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease risk; Area; Autopsy; Awareness; Biological Markers; Blood; Caregiver research; Caring; Characteristics; Charge; Clinical; Cognition; Cognitive; Communities; Data; Database Management Systems; Databases; Dementia; Development; Diagnosis; Disease; Disparity; Early Diagnosis; Educational Status; Elderly; Environment; Fostering; Funding; Future; Goals; Health Professional; Heterogeneity; Image; Impaired cognition; Individual; International; Intervention; Investigation; Measures; Mentors; Methods; Mission; Outcome; Participant; Pathologic; Pathology; Persons; Phenotype; Population; Population Heterogeneity; Prevention; Prevention strategy; Qualifying; Research; Research Activity; Research Design; Research Infrastructure; Research Methodology; Research Personnel; Research Support; Resources; Risk Factors; Risk Reduction; Scanning; Science; Secure; Services; Technology; Training and Education; Translational Research; Vascular Diseases; Vision; Walking; aging brain; brain health; career; caregiving; cohort; collaborative environment; dementia risk; design; disparity reduction; education research; effective therapy; epidemiology study; ethnic minority population; ethnoracial; high risk; imaging biomarker; improved; innovation; insight; interdisciplinary collaboration; interest; neuropathology; next generation; novel; prevent; racial minority population; recruit; risk mitigation; stem; therapy development; tool; training opportunity

PROJECT SUMMARY/ABSTRACT - Overall The mission of the UC Davis Alzheimer’s Disease Research Center (UCD ADRC) is to promote a highly innovative and enriched research environment focused on understanding the heterogeneity of brain aging among diverse populations that will ultimately lead to effective therapies to prevent or mitigate dementia. This approach stems from the premise that emphasizing diversity enhances discovery and contributes to translational science as well as reducing disparities in brain health and care. To accomplish this mission, the UCD ADRC has developed innovative methods and a unique study design to recruit and retain a highly demographically diverse clinical and autopsy cohort. All UCD ADRC participants are longitudinally followed and deeply phenotyped with extensive clinical, blood and imaging biomarker measures as well as developing state-of-the-art quantitative neuropathology. The UCD ADRC succeeds at these efforts through a robust research infrastructure, state-of-the-art database management and a highly collaborative environment consisting of seven well integrated resource cores and one research education component (REC) designed to facilitate new research efforts and interventions, dissemination of research findings, education and training as well as encouraging researcher development. Our approach addresses several milestones set by the National Alzheimer’s Project Act to effectively treat Alzheimer’s disease and associated disorders (ADRD) by 2025. These include, but are not limited to: 1) M1.L., evaluating disparities among ethnic and racial minority populations that are at higher risk for AD to mitigate risk and improve cognitive outcomes, 2) M2.H., fully characterizing mixed pathologies and identifying unique risk factors,3) M5-7., accelerating the development of treatments that would prevent, halt, or reverse the course of Alzheimer’s disease (AD), 4) M9., improving early diagnosis through discovery of novel imaging and blood biomarkers, 5) M8., developing novel dementia prevention strategies, and 6) M13.E.,supporting caregiving through funded caregiver research. The UCD ADRC also directly supports multiple epidemiological studies of diverse communities through use of research methods and personnel to gain further insights into dementia risk reduction, early diagnosis, and the impact of various neuropathologies on aging and dementia. Our efforts reflect the evolving needs of an increasingly older and more diverse US population, which is expected to rise to nearly 14 million by midcentury. Moreover, while AD continues to be the major pathological cause of dementia, more recent studies—including one from the UCD ADRC—find that dementia pathology is multifactorial and highly heterogeneous, due in part to the co-occurrence of AD and vascular disease, which varies by ethnoracial characteristics, is emphasized as part of dementia prediction and which can be modified by treatment even in later life. The UCD ADRC is uniquely qualified to support this research focus with a considerable impact on future ADRD diagnosis and treatment.

项目总结/摘要-总体 加州大学戴维斯分校阿尔茨海默病研究中心（UCD ADRC）的使命是促进一个高度 创新和丰富的研究环境，专注于了解大脑衰老的异质性 在不同的人群中，这将最终导致有效的治疗方法，以预防或减轻痴呆症。 这种方法源于这样一个前提，即强调多样性可以增强发现， 转化科学以及减少大脑健康和护理方面的差距。为了实现这一 使命，UCD ADRC开发了创新的方法和独特的研究设计，以招募和保留一个 高度人口统计学多样化临床和尸检队列。所有UCD ADRC参与者都是纵向的 随访并通过广泛的临床、血液和成像生物标志物测量进行深入的表型分析， 发展最先进的定量神经病理学UCD ADRC通过一个 强大的研究基础设施，最先进的数据库管理和高度协作的环境 由七个整合良好的资源核心和一个研究教育组成部分（REC）组成， 促进新的研究工作和干预措施，传播研究成果， 并鼓励研究人员的发展。我们的方法解决了国家安全局设定的几个里程碑 阿尔茨海默病项目法案，到2025年有效治疗阿尔茨海默病和相关疾病（ADRD）。 这些包括但不限于：1）M1.L.，评估少数民族和少数种族之间的差距 在AD风险较高的人群中减轻风险并改善认知结果，2）M2.H.，充分 表征混合病理并识别独特的风险因素，3）M5-7.，加快发展 将预防、停止或逆转阿尔茨海默病（AD）进程的治疗，4）M9.，改进早期 通过发现新的成像和血液生物标志物进行诊断，5）M8.，发展新型痴呆症 预防战略，以及6）M13.E.，通过资助看护者研究支持康复。的UCD ADRC还通过使用研究直接支持不同社区的多项流行病学研究， 方法和人员，以进一步了解痴呆症的风险降低，早期诊断， 对衰老和痴呆症的各种神经病理学。 我们的努力反映了日益老龄化和多样化的美国人口不断变化的需求， 预计到本世纪中叶将增加到近1400万人。此外，虽然AD仍然是主要的病理性疾病， 痴呆症的原因，最近的研究-包括来自UCD ADRC的一项研究-发现痴呆症的病理学是 多因素和高度异质性，部分原因是AD和血管疾病的共同发生， 因民族特征而异，强调作为痴呆症预测的一部分，并可进行修改 即使是在晚年也要接受治疗。UCD ADRC是唯一有资格支持这一研究重点， 对未来ADRD的诊断和治疗有相当大的影响。

项目成果

Cholesterol, Amyloid Beta, Fructose, and LPS Influence ROS and ATP Concentrations and the Phagocytic Capacity of HMC3 Human Microglia Cell Line.

• DOI: 10.3390/ijms241210396
• 发表时间: 2023-06-20
• 期刊: International journal of molecular sciences
• 影响因子: 5.6

Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET.

使用全身 EXPLORER PET 对 18F-florbetaben 进行无创定量。

• DOI: 10.21203/rs.3.rs-3764930/v1
• 发表时间: 2023
• 期刊: Research square
• 作者: Holy,EmilyN;Li,Elizabeth;Bhattarai,Anjan;Fletcher,Evan;Alfaro,EvelynR;Harvey,DanielleJ;Spencer,BenjaminA;Cherry,SimonR;DeCarli,CharlesS;Fan,AudreyP
• 通讯作者: Fan,AudreyP

Resources for Enhancing Alzheimer's Caregiver Health in Vietnam (REACH VN): study protocol for a cluster randomized controlled trial to test the efficacy of a family dementia caregiver intervention in Vietnam.

• DOI: 10.1186/s13063-022-06228-6
• 发表时间: 2022-05-09
• 期刊: Trials
• 影响因子: 2.5

Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers.

• DOI: 10.3390/ijms231810490
• 发表时间: 2022-09-10
• 期刊: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
• 影响因子: 5.6
• 作者: Kim, Si Eun;Kim, Hee Jin;Jang, Hyemin;Weiner, Michael W.;DeCarli, Charles;Na, Duk L.;Seo, Sang Won
• 通讯作者: Seo, Sang Won

Cardiovascular health and cognitive outcomes: Findings from a biracial population-based study in the United States.

心血管健康和认知结果：美国一项基于混血人口的研究的结果。

• DOI: 10.1002/alz.13421
• 发表时间: 2023
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
• 作者: Dhana,Anisa;DeCarli,CharlesS;Dhana,Klodian;Desai,Pankaja;Holland,ThomasM;Evans,DenisA;Rajan,KumarB
• 通讯作者: Rajan,KumarB